Squalamine

Star1

DB06461InvestigationalSmall molecule

Investigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration.

Mechanism: Pharmacologically active on Sodium/hydrogen exchanger 3
Curator reviewed
Primary indication: Investigated for use/treatment in ovarian cancer, lung cancer, and macular degeneration.Curator reviewed
Formula / weight: C₃₄H₆₅N₃O₅S · 627.97 g/mol (avg)
Code names: MSI-1246

Resolves to

Compound

UNIIF8PO54Z4V7CAS148717-90-2ChEMBLCHEMBL444929ChEBI80765KEGGC16841

Structure

InChIKeyUIRKNQLZZXALBI-MSVGPLKSSA-NSMILESCC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@H]4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)NCCCNCCCCN)OS(O)(=O)=O

Targets

P48764SLC9A3P04085PDGFAP09038FGF2O43915VEGFDP49767VEGFCP49765VEGFBP15692VEGFA

What you can answer from here — as of September 16, 2026

7Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

71Drug interactionsStructured to mechanism, not free text

11Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Squalamine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account